10 in stock
LL-37 5 mg is a human cathelicidin peptide attracting significant research interest for its broad antimicrobial activity, biofilm regulation, immune signalling and promising role in epithelial migration and wound repair.
Human Cathelicidin Peptide
37 Amino Acids
Host Defence and Repair
Laboratory to Topical Phase II
LL-37 is the only identified human member of the cathelicidin antimicrobial-peptide family. It is released when the precursor protein hCAP18 is processed into a 37-amino-acid peptide beginning with two leucine residues—giving LL-37 its name.
The peptide is produced by neutrophils, macrophages, epithelial cells and other tissues involved in early host defence. Researchers have identified it in the skin, respiratory tract, gastrointestinal tract and several body fluids.
Importantly, LL-37 acts as more than a direct antimicrobial molecule. It can also influence chemotaxis, cytokine responses, epithelial-cell migration, angiogenesis and communication between innate and adaptive immune systems.
LL-37 is positively charged and amphipathic. In laboratory models, these properties help it interact with negatively charged microbial membranes, disrupt membrane integrity and contribute to rapid antimicrobial activity.
Research suggests LL-37 can interfere with bacterial adhesion, quorum sensing, biofilm-associated genes and the extracellular matrix that helps microbial communities remain organized.
LL-37 can recruit immune cells and modify cytokine or receptor activity. Depending on concentration and tissue context, its effects may support defence, resolve inflammation or intensify inflammatory signalling.
Skin research links LL-37 with keratinocyte migration, angiogenic signals and wound closure. Its expression rises near the edge of acute wounds but is reduced in some chronic wounds.
| Research Area | Encouraging Finding | Evidence Context |
|---|---|---|
| Antimicrobial activity | Laboratory studies report activity against diverse Gram-positive and Gram-negative bacteria, fungi and some enveloped viruses. | Primarily in-vitro and mechanistic research. |
| Biofilm research | Reviews describe inhibition of adhesion, quorum sensing and biofilm-associated pathways across multiple bacterial species. | Promising laboratory evidence; in-vivo questions remain. |
| Acute wound biology | LL-37 is strongly expressed at acute wound edges and appears to support re-epithelialization and keratinocyte migration. | Human tissue observations and laboratory models. |
| Topical phase I study | A small study in hard-to-heal venous leg ulcers reported good tolerability and encouraging effects on healing measures at lower concentrations. | Early human topical evidence. |
| Topical phase IIb trial | The full 148-person cohort did not show a significant overall advantage; however, a post-hoc large-wound subgroup produced a positive signal worthy of further study. | Randomized human trial with a promising subgroup observation. |
LL-37 provides a compelling template for studying membrane-disrupting activity and host defence against diverse microbial targets.
Research interest extends beyond planktonic cells to adhesion, matrix organization, quorum signalling and biofilm-resident microbial communities.
The peptide’s positive links with keratinocyte migration, angiogenesis and wound-edge expression make it notable in skin and mucosal repair research.
LL-37 is widely studied as a bridge between direct antimicrobial defence and receptor-driven immune-cell recruitment or cytokine regulation.
LL-37 is unusual among many experimental peptides because topical wound research has progressed into controlled human trials. In an early study, topical concentrations of 0.5, 1.6 and 3.2 mg/mL were evaluated in hard-to-heal venous leg ulcers. The material was reported as safe and well tolerated, with the strongest healing signals appearing at the two lower concentrations.
A later phase IIb study randomized 148 participants to topical LL-37 at 0.5 or 1.6 mg/mL or placebo alongside compression care. The trial did not find a significant improvement across the complete population. Nevertheless, a post-hoc analysis found statistically significant improvements in several healing measures among participants whose wounds were at least 10 cm².
| Research Setting | Route Studied | What It Establishes |
|---|---|---|
| Microbial and biofilm models | Direct laboratory exposure | Mechanism and concentration-response signals. |
| Cell and tissue repair models | Direct cellular or tissue exposure | Migration, signalling and re-epithelialization findings. |
| Human venous-ulcer trials | Topical wound application | Early tolerability and wound-healing signals in a specific topical formulation. |
| Subcutaneous discussion | Not clinically standardized | No validated human subcutaneous dose, schedule or efficacy profile. |
Published topical concentrations belong to supervised wound-product trials and should not be converted into a different administration route. The 5 mg vial size describes total laboratory quantity, not an established individual dose.
The evidence surrounding LL-37 5 mg is scientifically rich. Its natural role in human innate immunity is well established, and the antimicrobial, antibiofilm and wound-repair findings create several promising research directions.
At the same time, activity varies with concentration, salt, serum, microbial species and tissue environment. LL-37 is not simply “on” or “off”: it can support protective inflammation in one setting and contribute to excessive inflammatory signalling in another. Therefore, results from one model should not automatically be generalized to another.
Human research is strongest for specially formulated topical wound applications. Antimicrobial and biofilm claims remain primarily laboratory-based, and validated systemic or subcutaneous protocols have not been established.
LL-37 5 mg is supplied for analytical, laboratory and research applications involving antimicrobial activity, host-defence signalling, biofilm biology and wound-repair pathways.
For research use only. Not for human or veterinary use. This information is educational and does not constitute medical advice or establish safety, efficacy or an administration protocol.
